Vitreal penetration of oral moxifloxacin in humans

Retina

Volumn 28, Issue 3, 2008, Pages 473-476

  Lott, McGregor N ^a   Fuller, Jeffrey J ^b   Hancock, Heather A ^c   Singh, Jasleen ^d   Singh, Harinderjit ^e   McGwin Jr , Gerald ^f   Marcus, Dennis M ^c,e  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Retina and Vitreous of Louisiana   (United States)

^c UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

^e Southeast Retina Center   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Endophthalmitis; Endophthalmitis prophylaxis; Endophthalmitis treatment; Moxifloxacin; Postoperative endophthalmitis; Vitreal penetration

Indexed keywords

MOXIFLOXACIN;

ADULT; AGED; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CILIARY DISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC RETINOPATHY; DIARRHEA; DRUG PENETRATION; EPIRETINAL MEMBRANE; FEMALE; HUMAN; MALE; NAUSEA; RETINA DETACHMENT; RETINA MACULA CYSTOID EDEMA; RETINA MACULA HOLE; SINGLE DRUG DOSE; SUBRETINAL NEOVASCULARIZATION; UVEITIS; VITRECTOMY; VITREOUS BODY; VITREOUS HEMORRHAGE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; ANTIBIOTIC PROPHYLAXIS; AZA COMPOUNDS; ENDOPHTHALMITIS; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; QUINOLINES; VITRECTOMY; VITREOUS BODY;

EID: 40449137689     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31814fb0ed     Document Type: Article

References (11)

1. Costello P, Bakri SJ, Beer PM, et al. Vitreous penetration of topical moxifloxacin and gatifloxacin in humans. Retina 2006;26:191-195.
2. Hariprasad SM, Blinder KJ, Shah GK, et al. Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous. Arch Ophthalmol 2005;123:39-44.
3. Hariprasad SM, Shah GK, Mieler WF, et al. Vitreous and aqueous penetration of orally administered moxifloxacin in humans. Arch Ophthalmol 2006;124:178-182.
4. Vedantham V, Lalitha P, Velpandian T, Ghose S, Mahalakshmi R, Ramasamy K. Vitreous and aqueous penetration of orally administered moxifloxacin in humans. Eye 2007 (in press).
5. Fuller JJ, Lott MN, Henson NM, et al. Vitreal penetration of oral and topical moxifloxacin in humans. Am J Ophthalmol 2007;143:338-340.
6. Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study: a randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol 1995;113:1479-1496.
7. Fiscella RG, Nguyen TK, Cwik MJ, et al. Aqueous and vitreous penetration of levofloxacin after oral administration. Ophthalmology 1999;106:2286-2290.
8. Ozturk F, Kortunay S, Kurt E, Ilker SS, Basci NE, Bozkurt A. Penetration of topical and oral ciprofloxacin into the aqueous and vitreous humor in inflamed eyes. Retina 1999;19:218-222.
9. Talwar D, Kulkarni A, Azad R, et al. Intraocular ciprofloxacin levels after oral administration in silicone oil-filled eyes. Invest Ophthalmol Vis Sci 2003;44:505-509.
10. Hariprasad SM, Mieler WF, Holz ER. Vitreous and aqueous penetration or orally administered gatifloxacin in humans. Arch Ophthalmol 2003;121:345-350.
11. Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12.-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin, and ciprofloxacin. J Antimicrob Chemother 1997;40:639-651.